1. Israel Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Nextage Therapeutics Ltd

Nextage Therapeutics Ltd

NXTG.TA
Nextage Therapeutics LtdIL flagTel Aviv Stock Exchange
43.40
ILA
- -
- -
35.18MMarket Cap
Nextage Therapeutics Ltd
NXTG.TA
(Tel Aviv Stock Exchange)

Recent

price

43.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.06
0.49
- -
0.38
0.02
- -
- -
0.25
0.1
- -
Revenue per Share
-18.28
-6.98
-1.21
-2.51
-1.4
-0.3
-0.2
0.06
-0.26
- -
Basic EPS, GAAP
-14.68
-6.92
-3.43
-2.61
-0.55
-0.15
-0.22
-0.11
0.02
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
5.42
-1.28
-3.35
0.13
-0.01
0.74
0.7
-2.01
- -
Book Value per Share
- -
-5.56
-4.92
-3.1
0.01
0.02
-0.02
-0.09
-0.6
- -
Tangible Book Value per Share
- -
1
1
2
11
26
28
30
34
- -
Basic Weighted Avg Shares
- -
- -
- -
1
- -
- -
- -
8
3
4
Sales/Revenue/Turnover
-25,539.29
-1,462.96
- -
-634.81
-3,348.69
-7,825.27
- -
-69.76
-169.67
-226.46
Operating Margin (%)
1
1
- -
- -
- -
- -
- -
2
1
2
Depreciation Expense
-9
-6
-2
-5
-16
-8
-6
2
-9
-6
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-31,235.71
-1,415.31
- -
-653.3
-8,359.16
-8,492.31
- -
24.84
-273.49
-168.48
Profit Margin (%)
- -
2
-1
-5
1
2
- -
-3
-20
-27
Working Capital
- -
2
1
1
1
1
- -
- -
3
3
LT Debt
- -
4
-2
-6
1
1
- -
-3
-20
14
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-257.56
- -
- -
- -
- -
- -
9.03
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
152.22%
-169.13%
Free Cash Flow
- -
-250.15%
-1,102.93%
Net Income, GAAP
- -
-162.02%
-31.27%
Sales/Revenue/Turnover
- -
- -
11.57%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
8
2024
- -
- -
- -
- -
3
2025
- -
- -
- -
- -
4

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.06
2024
- -
- -
- -
- -
-0.26
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Yuyu Pharma, Inc. (000227.KS)
Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS)
Evotec SE (EVT.DE)
Venture Life Group plc (VLG.L)
Percheron Therapeutics Limited (PER.AX)
Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY)
Business
Nextage Therapeutics Ltd is an Israeli biotechnology firm concentrating on advanced drug delivery systems for the central nervous system. The company specializes in innovative technologies designed to transport medications effectively across the blood-brain barrier, aiming to address conditions such as Alzheimer's, Parkinson's, and certain cancers. While previously involved in cannabinoid-based and psychedelic product development through a merged subsidiary, its primary emphasis now centers on its Brain Targeting Liposome System (BTLS) platform. The company is based in Ness Ziona.